RSS   Newsletter   Contact   Advertise with us
Post Online Media

Motif Bio appoints Robert Dickey as CFO

Motif BioMotif Bio plc (Motif), a clinical stage biopharmaceutical company, announces that Robert Dickey IV has been appointed as chief financial officer.
Mr. Dickey is an accomplished financial professional with senior leadership experience in private and public healthcare companies.

Prior to joining Motif Bio, Mr. Dickey was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company.

He previously held senior leadership positions at NeoStem, Inc. (now known as Caladrius Biosciences Inc.), Hemispherx Biopharma Inc., Stemcyte Inc., Locus Pharmaceuticals Inc. and Protarga Inc.

Mr. Dickey began his career as an Investment Banker at Lehman Brothers and Legg Mason Wood Walker Inc.

Pete Meyers is leaving Motif Bio and has agreed to transition the CFO responsibilities to Mr. Dickey over the course of the next several weeks.

 

 LATEST MOVES FROM New York 


 
 

POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.